$5 Billion Raised by Demis Hassabis’ New AI Venture

Isomorphic Labs raises $5 billion

Isomorphic Labs, the drug discovery startup founded by former Google DeepMind chief Demis Hassabis, raised $5 billion in a Series C funding round on Tuesday. The investment, co-led by Greenoaks and Sequoia Capital with participation from Andreessen Horowitz and Google’s parent company, Alphabet, marks a large increase in capital for AI-driven pharmaceutical research, CNBC reported.

This funding arrives three-and-a-half months after Hassabis stepped down as CEO of DeepMind, the artificial intelligence lab he co-founded and later sold to Google in 2014, according to CNBC. The company previously closed a $2.1 billion Series B round in May.

Scaling AI-driven drug development

The new capital will support the design and development of new medicines by using proprietary AI models. The startup aims to build foundational biology models to better understand systemic diseases and move its first therapeutic programs into clinical trials, Hassabis said in a statement provided to CNBC.

“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI,” Hassabis said.

Fortune - Fortune 500 Daily & Breaking Business News
Photo: fortune.com

Isomorphic has operated as a standalone startup since spinning out of DeepMind in 2021. The firm focuses on a proprietary drug design engine that creates a pipeline of therapeutic candidates, according to CNBC.

Record investment in AI healthcare

The broader drug discovery sector has attracted record levels of capital throughout 2026 as investors look to capitalize on AI-driven medical breakthroughs. According to data from the deal-counting platform Dealroom, drug discovery startups have raised $23.2 billion so far in 2026, CNBC reported.

OpenAI established a partnership with Novo Nordisk in April, and Anthropic launched its own AI drug discovery program in June, CNBC noted.

Questions about Isomorphic Labs investors and funding goals

Who are the primary investors in Isomorphic Labs?

The Series C round was co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz also participated, alongside Alphabet, the parent company of Google.

What is the primary goal of the new funding?

Isomorphic Labs intends to use the $5 billion to accelerate the development of its proprietary drug design engine. The company plans to advance its internal pipeline of therapeutic candidates toward clinical trials.

How does this funding compare to previous rounds?

This $5 billion Series C follows a $2.1 billion Series B round that the company closed in May.

The $23.2 billion raised by drug discovery startups in 2026 represents a record figure for the industry, according to data from Dealroom.